eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N-transcaffeoyltyramine (NCT).
According to eXoZymes, the company will transfer its NCT manufacturing process to Curia who will scale the process at its facilities in León, Spain, and Rozzano, Italy. The work includes cross validation of eXoZymes’ proprietary, enzyme fermentation, cell-free reaction, and purification processes to support larger-scale and eventual commercial manufacturing. The program also includes process modeling and engineering analysis to define a recommended path to larger-scale manufacturing, further de-risking eXoZymes’ route to commercial NCT supply.
In a statement, Damien Perriman, CEO of eXoZymes, commented, “We are advancing the work required to establish the manufacturing pathway and supply chain to support NCT’s planned commercial launch. The Curia engagement establishes the manufacturing foundation required to support commercial customer qualification, future supply agreements, and the planned market introduction of NCT.”
